Prilosec
This article was originally published in The Tan Sheet
Executive Summary
Manhattan federal judge rejects AstraZeneca assertion generic omeprazole would infringe patent for active metabolites of Prilosec. '499 patent encompasses synthetic sulphenamides only, not those produced through in vivo conversion of omeprazole, court concludes May 29. Rulings on three antibiotic-related Prilosec patents expected in August in AstraZeneca's ongoing litigation against four generic firms. Basic omeprazole patent expires in October. Last year, two FDA advisory committees voted against OTC episodic heartburn relief indication for Prilosec but left open possibility of a chronic heartburn indication